Lilly to Acquire Merida for Autoantibody Degradation

Companies: Eli Lilly / Merida Biosciences · Deal Type: Acquisition · Deal Value: Up to $2.875 Billion Cash · Lead Asset: MER511 (Graves’ Disease, Phase 1) · Date: August 31, 2026 Summary Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in…